Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sandra M Swain

Showing results (181-190 of 210) with videos related to

Pageof 21
Sort By:
The Lancet. Oncology|October 8, 2013
Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trialAndré Robidoux, Gong Tang, Priya Rastogi, et al.
JAMA Oncology|March 28, 2024
Tumor Intrinsic Subtypes and Gene Expression Signatures in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Pooled Analysis of CALGB 40601, NeoALTTO, and NSABP B-41 TrialsAranzazu Fernandez-Martinez, Mattia Rediti, Gong Tang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 14, 2013
Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trialSandra M Swain, Gong Tang, Charles E Geyer, et al.
The Lancet. Oncology|August 15, 2015
Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trialHarry D Bear, Gong Tang, Priya Rastogi, et al.
The Lancet. Oncology|December 5, 2018
Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trialEleftherios P Mamounas, Hanna Bandos, Barry C Lembersky, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 19, 2012
Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancerEdward H Romond, Jong-Hyeon Jeong, Priya Rastogi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 10, 2021
Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN StudyIan E Krop, Seock-Ah Im, Carlos Barrios, et al.
The New England Journal of Medicine|January 27, 2012
Bevacizumab added to neoadjuvant chemotherapy for breast cancerHarry D Bear, Gong Tang, Priya Rastogi, et al.
Breast Cancer Research and Treatment|September 3, 2020
Risk factors for inflammatory and non-inflammatory breast cancer in North AfricaCatherine Schairer, Ahmed Hablas, Ibrahim AbdelBar Seif Eldein, et al.
The Lancet. Oncology|June 19, 2012
Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trialAlexander H G Paterson, Stewart J Anderson, Barry C Lembersky, et al.
Pageof 21

Showing results (181-190 of 210) with videos related to

Sort By:
Pageof 21
The Lancet. Oncology|October 8, 2013
Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trialAndré Robidoux, Gong Tang, Priya Rastogi, et al.
JAMA Oncology|March 28, 2024
Tumor Intrinsic Subtypes and Gene Expression Signatures in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Pooled Analysis of CALGB 40601, NeoALTTO, and NSABP B-41 TrialsAranzazu Fernandez-Martinez, Mattia Rediti, Gong Tang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 14, 2013
Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trialSandra M Swain, Gong Tang, Charles E Geyer, et al.
The Lancet. Oncology|August 15, 2015
Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trialHarry D Bear, Gong Tang, Priya Rastogi, et al.
The Lancet. Oncology|December 5, 2018
Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trialEleftherios P Mamounas, Hanna Bandos, Barry C Lembersky, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 19, 2012
Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancerEdward H Romond, Jong-Hyeon Jeong, Priya Rastogi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 10, 2021
Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN StudyIan E Krop, Seock-Ah Im, Carlos Barrios, et al.
The New England Journal of Medicine|January 27, 2012
Bevacizumab added to neoadjuvant chemotherapy for breast cancerHarry D Bear, Gong Tang, Priya Rastogi, et al.
Breast Cancer Research and Treatment|September 3, 2020
Risk factors for inflammatory and non-inflammatory breast cancer in North AfricaCatherine Schairer, Ahmed Hablas, Ibrahim AbdelBar Seif Eldein, et al.
The Lancet. Oncology|June 19, 2012
Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trialAlexander H G Paterson, Stewart J Anderson, Barry C Lembersky, et al.
Pageof 21